Merck’s tulisokibart meets its primary and key secondary endpoints in a Phase 2 hidradenitis suppurativa study but misses in systemic sclerosis-associated interstitial lung disease, Eli Lilly’s olomorasib receives a second FDA Breakthrough Therapy designation in KRAS G12C-mutant advanced pancreatic cancer, Eli Lilly removes its GBA1 gene therapy for Gaucher disease type 1 from its pipeline, Aravax’s PVX108 receives FDA Fast Track designation in peanut allergy, and Aspen Neuroscience’s sasineprocel receives FDA Regenerative Medicine Advanced Therapy designation in Parkinson’s disease: the most significant clinical trial results 7 August 2026 has to offer from across the pipeline.
This week delivered its news less through dedicated data releases than through the quarterly reporting season, when large developers set out in a single document what has worked, what has not, and what is being abandoned. The defining story is a mixed outcome for one of the most closely watched new immunology targets, where success in an inflammatory skin condition arrived alongside failure in a fibrotic lung disease, and the two together sharpen the question of how far the underlying mechanism will travel. Around it sat three regulatory designations spanning oncology, allergy and neurodegeneration, plus one programme termination disclosed without fanfare, a combination that captures how much of drug development is settled before any pivotal dataset exists. Here, Life Science Daily News brings you the most significant readouts and regulatory decisions of the week.
Merck’s Tulisokibart Succeeds in Hidradenitis Suppurativa and Fails in Scleroderma Lung Disease
Merck announced on 4 August 2026, alongside its second-quarter financial results, initial topline results from the primary analyses of two Phase 2 studies of tulisokibart (MK-7240), an investigational humanised monoclonal antibody targeting tumour necrosis factor-like cytokine 1A (TL1A). In hidradenitis suppurativa, a chronic inflammatory skin condition characterised by painful abscesses and nodules, the study met its primary and key secondary endpoints, and the company said full results will be shared at an upcoming medical meeting. In systemic sclerosis-associated interstitial lung disease, the study did not meet its primary endpoint and will be discontinued. No new safety concerns were identified in either study. Merck released no response rates or effect sizes for either result.
The split matters because Merck describes tulisokibart as carrying the broadest development programme in the anti-TL1A class, spanning seven indications, and because the thesis behind that breadth is that TL1A acts as a shared node across immuno-fibrotic disease rather than as a single-indication target. The molecule came to Merck through its 2023 acquisition of Prometheus Biosciences and delivered what the company said was the first Phase 3 success for an anti-TL1A biologic in June, when the ATLAS-UC induction-only study (Study 2, NCT06052059) met its primary endpoint of clinical remission by Modified Mayo Score at week 12 in moderately to severely active ulcerative colitis. Late-stage work continues in ulcerative colitis and in Crohn’s disease through ARES-CD, with Phase 2 studies ongoing in rheumatoid arthritis, psoriatic arthritis and radiographic axial spondyloarthritis. The discontinued study is notable for what it tested: scleroderma lung disease is the indication in that set where established fibrosis, rather than active inflammation, is the dominant driver of clinical decline, which makes it the setting in which the immuno-fibrosis rationale was most directly exposed.
Lilly’s Olomorasib Receives a Second Breakthrough Therapy Designation in KRAS G12C Pancreatic Cancer
Eli Lilly announced on 3 August 2026 that the US Food and Drug Administration has granted Breakthrough Therapy designation to olomorasib as a monotherapy for adults with advanced pancreatic cancer who have received at least one prior systemic therapy and whose tumours carry a KRAS G12C mutation, as determined by an FDA-approved test. Olomorasib (LY3537982) is an investigational oral, next-generation inhibitor of the KRAS G12C protein. The designation rests on preliminary results from the open-label, multicentre Phase 1/2 LOXO-RAS-20001 study (NCT04956640), which is evaluating olomorasib in patients with KRAS G12C-mutant advanced solid tumours, including those with pancreatic cancer who have progressed on prior systemic treatment. Lilly did not disclose response rates or survival data from the study.
This is the second Breakthrough Therapy designation for the molecule. The first, granted in September 2025, covered olomorasib in combination with pembrolizumab for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation and PD-L1 expression of at least 50 per cent. The pancreatic setting is considerably narrower. KRAS mutations drive roughly 90 per cent of pancreatic cancers, but the G12C variant specifically accounts for only about 1 to 2 per cent of cases, so the eligible population is a small fraction of an already difficult disease. American Cancer Society estimates for 2026 put new diagnoses in the United States at 67,530 and deaths at 52,740, and SEER data place five-year relative survival for distant-stage disease at around 3 per cent. There is currently no FDA-approved therapy indicated specifically for KRAS G12C-mutant pancreatic cancer. Jacob Van Naarden, executive vice president and president of Lilly Oncology, said in the company’s announcement that the designation reflects the early potential seen with olomorasib in this setting. The drug is also being studied in the pivotal, registrational SUNRAY-01 study and in SUNRAY-02, both in non-small cell lung cancer.
Lilly Removes Its GBA1 Gene Therapy for Gaucher Disease Type 1 From the Pipeline
Eli Lilly’s second-quarter results, published on 5 August 2026, carried a pipeline update that removed the Phase 1/2 PROCEED study of LY3884961 in Gaucher disease type 1. PROCEED (NCT05487599) was an open-label, dose-finding study of a single intravenous dose of the adeno-associated virus gene therapy, which delivers a functional copy of the GBA1 gene, in adults with peripheral manifestations of the disease. The study started in December 2022, and the design called for up to three dose levels across cohorts of three patients, followed by an expansion cohort of up to six. The ClinicalTrials.gov record had not been updated to reflect the decision at the time of writing and still listed the study as recruiting. Lilly told trade press that the programme did not meet its internal bar for success, that no safety signal was observed, and that it is continuing the GBA1 gene therapy programme in Parkinson’s disease.
The decision effectively closes the Gaucher chapter of Lilly’s acquisition of Prevail Therapeutics, agreed in late 2020. Prevail brought two lead gene therapies into that deal. The frontotemporal dementia candidate LY3884963 was removed from the pipeline in February 2026, and development in Gaucher disease type 2 had already been discontinued in early 2024, although the PROVIDE study of infants already dosed remains listed as active and not recruiting. What survives of the acquired GBA1 programme is the Parkinson’s indication, alongside gene therapies for otoferlin-mediated hearing loss and vestibular schwannoma acquired through Lilly’s 2022 purchase of Akouos. Gaucher disease type 1 is caused by biallelic pathogenic variants in GBA1 that leave patients deficient in the enzyme glucocerebrosidase, and it is already manageable with enzyme replacement and substrate reduction therapy. That existing standard of care sets a demanding bar for any one-time genetic medicine, which has to justify irreversibility against treatments that work and can be stopped. Spur Therapeutics dosed the first patient in July in GALILEO-3, a pivotal Phase 3 trial of a competing GBA1 gene therapy, avigbagene parvec, in the same indication.
Aravax’s PVX108 Receives FDA Fast Track Designation for Peanut Allergy
Aravax announced on 3 August 2026 that the FDA has granted Fast Track designation to PVX108, its lead candidate for the treatment of peanut allergy. PVX108 is a next-generation immunotherapy that uses proprietary peptides designed to retrain the immune system to tolerate peanut while avoiding the treatment-induced acute allergic reactions associated with whole-allergen approaches. Fast Track designation makes a candidate eligible for more frequent meetings and written communication with the agency, for Accelerated Approval and Priority Review where the relevant criteria are met, and for rolling review, under which completed sections of a marketing application can be submitted as they are finished rather than held back until the full application is ready.
The company reports that Phase 2 studies are ongoing at clinics in the United States and Australia, with key data anticipated later in 2026. Pascal Hickey, Chief Executive of Aravax, said there remains a critical need for effective new treatments for food allergy and that the ability to communicate more frequently with the agency often shortens the path to patient access. It is worth stating plainly that this is a procedural milestone rather than an efficacy signal: no Phase 2 efficacy or safety results have been reported, and the designation does not indicate that the treatment works. That readout is the meaningful test. Established peanut allergy immunotherapy works by gradual desensitisation using the allergen itself, an approach that carries a persistent risk of reaction during treatment and demands sustained adherence over years. That option has just narrowed. Stallergenes Greer discontinued Palforzia, the only oral immunotherapy licensed for peanut allergy in the United States and the United Kingdom, on 31 July, three days before the Fast Track announcement, leaving no licensed immunotherapy for the condition in either market. A peptide-based candidate that avoids whole-allergen exposure would answer the principal tolerability objection to the desensitisation model, but only if it can show a clinically meaningful change in how much peanut protein patients can tolerate on food challenge.
Aspen Neuroscience’s Sasineprocel Granted RMAT Designation in Parkinson’s Disease
This story broke on 30 July, one day outside this week’s coverage window, and was not included in last week’s roundup. Given its clinical significance, we are covering it here.
Aspen Neuroscience announced on 30 July 2026 that the FDA has granted Regenerative Medicine Advanced Therapy designation to sasineprocel (ANPD001), its lead investigational cell therapy for Parkinson’s disease. The designation is based on results from the ongoing Phase 1/2a ASPIRO trial, an open-label, multicohort, multicentre study evaluating the safety, tolerability and activity of surgically delivered autologous dopaminergic neuron precursor cells into the putamen, the region of the brain where restoration of dopamine signalling is needed. Aspen described the trial as having demonstrated encouraging early clinical activity and a favourable safety profile, but released no figures alongside the announcement. The therapy had previously received Fast Track designation.
Sasineprocel is created from a patient’s own cells through a small skin punch biopsy, reprogrammed into induced pluripotent stem cells and then differentiated into dopaminergic neuron precursors before image-guided delivery to the putamen. Because the cells are autologous, the chronic immunosuppression required for donor-derived cell therapies is not needed, which is both the central design argument for the approach and its main practical differentiator from allogeneic competitors. The trade-off is manufacturing, since every dose is built for one patient. Aspen has previously reported that ASPIRO has dosed 15 patients across four cohorts, with 12-month safety showing no serious surgical adverse events, no severe graft-induced dyskinesia and no symptomatic haemorrhages or infarctions, alongside reductions in levodopa equivalent daily dose in some patients, and it has said it aims to begin a Phase 3 study later in 2026. RMAT designation, established under the 21st Century Cures Act, requires preliminary clinical evidence that a regenerative therapy has the potential to address an unmet need in a serious condition, and brings early and frequent interactions with the agency plus potential eligibility for priority review and accelerated approval. It is not an approval, and the ASPIRO evidence supporting it remains early, open-label and uncontrolled. The company published no response rates or comparative data alongside the designation itself.
Looking Ahead
This week’s clinical trial results 7 August 2026 came predominantly from quarterly reporting rather than dedicated data releases, and that shapes how much can honestly be said about them. Merck’s twin Phase 2 outcomes are the week’s most consequential development, and the candid reading is that neither result is quantified: a win and a loss were disclosed without effect sizes, which is ordinary practice in an earnings document but leaves the strength of the hidradenitis suppurativa result unknown until a medical meeting. The three designations awarded across pancreatic cancer, peanut allergy and Parkinson’s disease share a characteristic worth restating, which is that none of them is evidence of efficacy; each reflects a regulator’s judgement that early data justify a faster process, not that the process will end in approval. And a Phase 1/2 study quietly vanishing from a pipeline table is its own kind of finding, one that arrives without a press release and never with a dataset. Life Science Daily News will continue to bring you accurate, timely coverage of the trial readouts and regulatory decisions that matter most across the global life sciences pipeline.
